Stocktoria

Foghorn Therapeutics Inc. FHTX

Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-10-23
Chart by TradingView
1/9
Piotroski F — financial health
-10.28
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$30.9M$22.6M$34.2M$19.2M$1.3M
Operating income-$86.4M-$102.7M-$107.9M-$117.1M-$100.7M
Net income-$74.3M-$86.6M-$98.4M-$108.9M-$101.3M
Operating cash flow-$86.1M-$100.4M-$118.1M$193.6M-$50.2M
Free cash flow-$86.1M-$101.3M-$119.3M$192.4M-$53.6M
Total assets$198.1M$284.0M$285.9M$404.9M$519.8M
Total liabilities$306.6M$329.5M$363.1M$404.8M$422.9M
Shareholders' equity-$108.5M-$45.5M-$77.2M$112,000$96.9M
Ratios
Operating margin-279.5%-454.3%-315.9%-609.2%-7637.1%
Net margin-240.3%-383.2%-288.2%-566.3%-7681.6%
FCF margin-278.7%-448.2%-349.4%1000.6%-4060.9%
Return on assets-37.5%-30.5%-34.4%-26.9%-19.5%
Return on equity68.5%190.3%127.5%-97216.1%-104.6%
Debt / equity0.00×
Current ratio2.733.734.116.379.44
Revenue growth36.8%-33.8%77.6%1357.8%206.7%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC406,425$1.9M
Point72 Asset Management, L.P.27,646$132,148

Why these scores methodology →

Piotroski F-score: 1/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -10.28 (distress)

  • Working capital / assets 0.522
  • Retained earnings / assets -3.193
  • EBIT / assets -0.436
  • Equity / liabilities -0.354

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001822462 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.